Marekani - Kiingereza - NLM (National Library of Medicine)

major pharmaceuticals - rivastigmine tartrate (unii: 9iy2357jpe) (rivastigmine - unii:pki06m3iw0) - rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia of the alzheimer's type (ad). rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia associated with parkinson’s disease (pd). rivastigmine tartrate capsules are contraindicated in patients with: isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . risk summary    there are no adequate data on the developmental risks associated with the use of rivastigmine tartrate in pregnant women. in animals, no adverse effects on embryo-fetal development were observed at oral doses 2 to 4 times the maximum recommended human dose (mrhd) (see data) . the background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. d

Marekani - Kiingereza - NLM (National Library of Medicine)

modavar pharmaceuticals llc - rivastigmine tartrate (unii: 9iy2357jpe) (rivastigmine - unii:pki06m3iw0) - rivastigmine tartrate capsules, usp are indicated for the treatment of mild-to-moderate dementia of the alzheimer's type (ad). rivastigmine tartrate capsules, usp are indicated for the treatment of mild-to-moderate dementia associated with parkinson's disease (pd).  rivastigmine tartrate capsules are contraindicated in patients with: • known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see description (11)]. • a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see warnings and precautions (5.2)]. isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)]. risk summary there are no adequate data on the developmental risks associated with the use of rivastigmine tartrate in pregnant women. in animals, no adverse effects on embryo-fetal development were obs

Kanada - Kiingereza - Health Canada

pharmapar inc - rivastigmine - patch - 4.6mg - rivastigmine 4.6mg - parasympathomemetic (cholinergic) agents

Kanada - Kiingereza - Health Canada

pharmapar inc - rivastigmine - patch - 9.5mg - rivastigmine 9.5mg - parasympathomemetic (cholinergic) agents

Kanada - Kiingereza - Health Canada

pharmapar inc - rivastigmine - patch - 13.3mg - rivastigmine 13.3mg - parasympathomemetic (cholinergic) agents

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 2.4 mg - capsule - excipient ingredients: microcrystalline cellulose; stearic acid; gelatin; iron oxide yellow; maize starch; titanium dioxide; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 4.8 mg - capsule - excipient ingredients: titanium dioxide; microcrystalline cellulose; gelatin; maize starch; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 4.8 mg - capsule - excipient ingredients: iron oxide red; microcrystalline cellulose; gelatin; iron oxide yellow; stearic acid; titanium dioxide; maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 9.6 mg - capsule - excipient ingredients: gelatin; iron oxide red; stearic acid; titanium dioxide; microcrystalline cellulose; maize starch; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 9.6 mg - capsule - excipient ingredients: maize starch; microcrystalline cellulose; gelatin; iron oxide red; stearic acid; titanium dioxide; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type